Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial.Albrecht Kretzschmar, Dirk Arnold, Thomas Wolff et al.|Journal of Clinical Oncology|2010Cited by 0